Literature DB >> 15489905

Congenital afibrinogenaemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen Aalpha-chain gene.

Silvia Spena1, Stefano Duga, Rosanna Asselta, Flora Peyvandi, Chularatana Mahasandana, Massimo Malcovati, Maria Luisa Tenchini.   

Abstract

Among rare inherited deficiencies of coagulation factors, congenital afibrinogenaemia is characterised by the lack of fibrinogen in plasma. In the last few years, several genetic defects underlying afibrinogenaemia (mostly point mutations) have been described in the fibrinogen gene cluster. In this study, the molecular basis responsible for afibrinogenaemia in a Thai proband was defined. Point mutation screening was accomplished by directly sequencing the three fibrinogen genes. The impossibility to amplify fibrinogen Aalpha-chain gene (FGA) exons 5 and 6 suggested the presence of a homozygous deletion. A specific long-range PCR assay enabled the identification of a novel 15-kb deletion, representing the largest afibrinogenaemia-causing deletion described so far. Direct sequencing of the deletion junction allowed mapping of the breakpoints in FGA intron 4 and in the intergenic region between Aalpha- and Bbeta-chain genes. Since the mutation was inherited only from the mother and nonpaternity was ruled out, a maternal uniparental disomy (UPD) was hypothesised. UPD test, carried out with markers covering the whole chromosome 4, revealed that maternal isodisomy was responsible for homozygosity of the 15-kb deletion in the proband. The apparently normal phenotype of the proband, except for afibrinogenaemia, suggests that UPD for chromosome 4 is clinically silent. This represents the first case of a documented complete isodisomy of chromosome 4 causing the phenotypic expression of a recessive disorder. In silico analyses of the regions surrounding the breakpoints suggested that the 15-kb deletion might have originated from an inappropriate repair of a double-strand break by the nonhomologous end joining mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15489905     DOI: 10.1038/sj.ejhg.5201207

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  6 in total

1.  Deletion of GPIHBP1 causing severe chylomicronemia.

Authors:  Jonathan J Rios; Savitha Shastry; Juan Jasso; Natalie Hauser; Abhimanyu Garg; André Bensadoun; Jonathan C Cohen; Helen H Hobbs
Journal:  J Inherit Metab Dis       Date:  2011-10-19       Impact factor: 4.982

2.  Correlations between long inverted repeat (LIR) features, deletion size and distance from breakpoint in human gross gene deletions.

Authors:  Nevim Aygun
Journal:  Sci Rep       Date:  2015-02-06       Impact factor: 4.379

Review 3.  Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders.

Authors:  Giovanni Luca Tiscia; Maurizio Margaglione
Journal:  Int J Mol Sci       Date:  2018-05-29       Impact factor: 5.923

4.  Prenatal diagnosis of complete maternal uniparental isodisomy of chromosome 4 in a fetus without congenital abnormality or inherited disease-associated variations.

Authors:  WeiQiang Liu; HuiMin Zhang; Jian Wang; GuoJiu Yu; WenJun Qiu; ZhiHua Li; Min Chen; Kwong Wai Choy; XiaoFang Sun
Journal:  Mol Cytogenet       Date:  2015-11-04       Impact factor: 2.009

5.  Fibrinogen as a Pleiotropic Protein Causing Human Diseases: The Mutational Burden of Aα, Bβ, and γ Chains.

Authors:  Elvezia Maria Paraboschi; Stefano Duga; Rosanna Asselta
Journal:  Int J Mol Sci       Date:  2017-12-14       Impact factor: 5.923

6.  A homozygous duplication of the <I>FGG</i> exon 8-intron 8 junction causes congenital afibrinogenemia. Lessons learned from the study of a large consanguineous Turkish family.

Authors:  Michel Guipponi; Frédéric Masclaux; Frédérique Sloan-Béna; Corinne Di Sanza; Namik Özbek; Flora Peyvandi; Marzia Menegatti; Alessandro Casini; Baris Malbora; Marguerite Neerman-Arbez
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 11.047

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.